Treosulfan
Transplant-Related Hematologic Malignancy
IRCCS San RaffaeleSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Transplant-Related Hematologic Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine IRCCS San Raffaele | Phase 2 | B |
Cytosin-Arabinosid Ciceri Fabio | Phase 2 | B |
Thiotepa Ciceri Fabio | Phase 2 | B |
Revumenib Center for International Blood and Marrow Transplant Research | Phase 2 | CCC |
Monomethyl Fumarate IRCCS San Raffaele | Phase 1 | CC |
View all 10 →
Same molecule, other indications
Treosulfan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →